NCT05645718View on ClinicalTrials.gov

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Leukemia
Interventions
DRUG

Cyclophosphamide

Given by (IV) vein

DRUG

Vincristine

Given by (IV) vein

DRUG

Blinatumomab

Given by (IV) vein

DRUG

Methotrexate

Given by (IV) vein

DRUG

Cytarabine

Given by (IV) vein

DRUG

Mercaptopurine

Given by (IV) vein

DRUG

Prednisone

Given by PO

DRUG

Pegfilgrastim

Given by (IV) vein

DRUG

Inotuzumab ozogamicin

Given by (IV) vein

DRUG

Rituximab

Given by (IV) vein

DRUG

Dexamethasone

Given by (IV) vein

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER